Immunocore Holdings plc Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Immunocore Holdings plc (IMCR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 290.52 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-06
- Immunocore Holdings plc share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 85.95K shares, a 139.75% increase year-over-year.
- Immunocore Holdings plc share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 204.57K shares, a 1450.60% increase year-over-year.
- Immunocore Holdings plc share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 21.43K shares.
- Immunocore Holdings plc share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-06-30 was 35.85K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month |
|---|---|---|---|
| 2026-06-30 | 85.95K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 290.52K shares 10-Q · filed 2026-08-06 | |
| 2026-03-31 | 204.57K shares 10-Q · filed 2026-05-06 | ||
| 2025-09-30 | 21.43K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 57.28K shares derived: sum of 2 quarters · filed 2025-11-06 | 70.47K shares 10-Q · filed 2025-11-06 |
| 2025-06-30 | 35.85K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 49.04K shares 10-Q · filed 2025-08-07 | |
| 2025-03-31 | 13.19K shares 10-Q · filed 2025-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |